Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

LEUVEN, Belgium, April 9 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, announces today that it has completed patient enrolment for its Phase II MITI IV study. The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients between four and twelve hours after the onset of the stroke.

MITI IV (Microplasmin in Treatment of Ischemic stroke - IntraVenous) is a Phase II, multicentre, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety of the intravenous administration of microplasmin in 40 patients with acute ischemic stroke. The trial is investigating three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) and placebo. The trial is also designed to provide preliminary efficacy data using radiographic assessments and plasma surrogate biomarkers. Clinical outcomes are assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments are performed.

Microplasmin is a truncated form of the natural human protein plasmin, which plays a key role in dissolving blood clots such as those that cause acute stroke. It is a direct-acting thrombolytic agent that has the potential to restore blood flow efficiently within an extended period after a stroke event and has potentially fewer side-effects than other thrombolytic agents. Currently the only approved pharmacologic treatment of acute ischemic stroke is tPA, an indirect-acting thrombolytic. However tPA must be administered within three hours after the stroke has occurred and has the risk of causing unwanted bleeding events.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have completed enrolment in this study. We look forward to the results, which shoul
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... PDS, a leader in providing smart an... announces Pajama Pathology®, evolutionizing w... ‘gold standard’ software used by 8 of... but on a ‘cost per slide’ basis. , ... November 30, 2009 -- PDS has announced another ev...
(Date:11/30/2009)... , LONDON, November 30 ...y, was named Europe,s fastest growing,Biotech/Phar... the Deloitte,2009 Technology Fast 500 for EMEA (E...nual ranking is based on a companies, five-year re...e of 8,318% over this period. This,achievement pla...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 Cromo...itiate water-soluble carbon nanotube-based cancer ...r-soluble carbon nanotubes, which have functional ...th cancer drugs, was developed in partnership with...ted carbon nanotubes serves as a drug delivery veh...
(Date:11/25/2009)... , DURHAM, N.C., Nov. 25 Resea...irst energy-efficient, single-treatment water puri... nanotubes to Andhra Pradesh, Minister of Rural Wa...rs in Hyderabad, India today. Initial tests, perfo...r, confirmed that the majority of the drinking wat...
Breaking Biology Technology:Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2
... 200 applicants has been winnowed to 52 in the Se...test . , ,An independent panel of judges selected ...contest. The judges were organized through the Wi...e contest in conjunction with its membership subsi... statewide affiliates. , ,"Our judges were impress...
...Wis. Information-technology businesses are takin...ther. With the Fusion 2005 CEO-CIO Symposium on ...rts watching IT in Wisconsin offered their opinion...ing their business practices as the year progresse...att Miszewski, CIO for the state of Wisconsin, sev...
...ce Learning Inc. , a provider of education product...ing Systems LLC to the subsidiary,s president, Joh...e taxes on $2.6 million in sales in 2004. Renaissa...rnatives over the past few years and decided the s... will record a $600,000 gain for the sale, includi...
Other Biology Technology:Contest narrows to 52 business plans 2Restructuring is a watchword for IT in 2005 2Restructuring is a watchword for IT in 2005 3
(Date:11/26/2009)... eight European countries has shown that closing s...mic could have a significant role in reducing illn...access journal BMC Infectious Diseases compared ...kends/holidays, finding that they were reduced whe...d Antwerp University, Belgium, led a team of Europ...
(Date:11/26/2009)...mber 2009 What are the bare essentials of life, t... cell that can survive on its own? Can we describe...ow an entire organism functions as a system? These... a partnership between the European Molecular Biol...the Centre de Regulacio Genmica (CRG) in Barcelona...
(Date:11/25/2009)...sts at the California Institute of Technology (Cal...on-like behavior in the fruit fly, Drosophila mel...ant to the relationship between the neurotransmitt...sorder (ADHD), are described in the December issue...in contains only about 20,000 neurons and has long...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Report 3A Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Prevent 49091 1Report 3A Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Prevent 49091 2Report 3A Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Prevent 49091 3Report 3A Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Prevent 49091 4Report 3A Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Prevent 49091 5Analysis of drug eluting stents data demonstrates safety efficacy in on and off label use 49087 1Analysis of drug eluting stents data demonstrates safety efficacy in on and off label use 49087 2Greater Boston unites to transform health care 49083 1Greater Boston unites to transform health care 49083 2
...DNA can serve as a measure of the biological impac...ean-up. That,s one of the conclusions of a new stu...arch Institute (PNRI), Woods Hole Oceanographic In...onal Institute of Standards and Technology (NIST)....trated the adverse effects of industrial pollutant...
...on of gorillas during an Ebola outbreak in the rai... have found that in a few months the virus exhibit...p-dwelling and solitary gorillas. The findings off... threat the deadly virus poses to great apes. , T...journal Current Biology by a team of researchers i...
...ghter controls on the live reef fish trade, a grow...national journal Science. , Twenty of the world,s...the Department of Zoology, University of Cambridge...e unsustainable plunder of the world,s ocean resou...attled for survival against a complex array of thr...
Other Biology News:Precision biochemistry tracks DNA damage in fish 2Gorilla susceptibility to Ebola virus: the cost of sociality 2Researchers appeal for new regulations to save coral reefs from live fish trade 2Researchers appeal for new regulations to save coral reefs from live fish trade 3
EDG-6 Lysate from Exalpha Biologicals, Inc.
Anti-Indoleamine 2,3-dioxygenase (IDO) Monoclonal Antibody, Unconjugated from CHEMICON
Mouse Anti-RYK Monoclonal Antibody, Unconjugated, Clone F30 P7 D7 F5 from Abcam
Anti-G Protein Gq / 11a Subunit, Internal Sequence, a.a. 115-133 Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: